Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study

13 hours ago 5

The operation of Roche’s investigational drug, giredestrant, with Pfizer’s Ibrance didn’t pb to a statistically important betterment among patients with precocious bosom cancer.

Read Entire Article

Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study

Related

Wegovy maker Novo Nordisk said it is teaming up with Hims & ...

GSK Sells Rights to Drug Candidate to Alfasigma for Up to $6...

Sent 90 miles after giving birth while 'soaked in urine'

Popular

Formula One comes to Apple TV: Everything you need to know a...

Meta to Create New Applied AI Engineering Organization

Former Barclays Center Executive Says Live Nation Threatened...

Colorado Governor Signals He’ll Commute Sentence of Election...

Is He the Last Man in Naples, Italy, to Paint Numbers By Han...